AR074777A1 - Proteinas de union a antigeno - Google Patents

Proteinas de union a antigeno

Info

Publication number
AR074777A1
AR074777A1 ARP090104946A ARP090104946A AR074777A1 AR 074777 A1 AR074777 A1 AR 074777A1 AR P090104946 A ARP090104946 A AR P090104946A AR P090104946 A ARP090104946 A AR P090104946A AR 074777 A1 AR074777 A1 AR 074777A1
Authority
AR
Argentina
Prior art keywords
antigen binding
binding proteins
proteins
antigen
union
Prior art date
Application number
ARP090104946A
Other languages
English (en)
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41786068&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR074777(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of AR074777A1 publication Critical patent/AR074777A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Abstract

Proteínas de unión a antígeno, tales como anticuerpos, que se unen a miostatina, a polinucleótidos que codifican dichas proteínas de unión a antígeno, a composiciones farmacéuticas que comprenden dichas proteínas de unión a antígenos y a procedimientos para su fabricación, también se refiere al uso de dichas proteínas de unión a antígeno en el tratamiento o profilaxis de enfermedades asociadas con una cualquiera o una combinación da reducción de masa muscular, fuerza muscular y función muscular.
ARP090104946A 2008-12-19 2009-12-17 Proteinas de union a antigeno AR074777A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US13898008P 2008-12-19 2008-12-19

Publications (1)

Publication Number Publication Date
AR074777A1 true AR074777A1 (es) 2011-02-09

Family

ID=41786068

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP090104946A AR074777A1 (es) 2008-12-19 2009-12-17 Proteinas de union a antigeno

Country Status (24)

Country Link
US (1) US20110256132A1 (es)
EP (1) EP2358753A1 (es)
JP (1) JP2012512641A (es)
KR (1) KR20110103431A (es)
CN (1) CN102325793A (es)
AR (1) AR074777A1 (es)
AU (1) AU2009329533A1 (es)
BR (1) BRPI0922405A2 (es)
CA (1) CA2747062A1 (es)
CL (1) CL2011001503A1 (es)
CO (1) CO6400149A2 (es)
CR (1) CR20110358A (es)
DO (1) DOP2011000189A (es)
EA (1) EA201190018A1 (es)
IL (1) IL213243A0 (es)
MA (1) MA32980B1 (es)
MX (1) MX2011006611A (es)
NZ (1) NZ593297A (es)
PE (1) PE20120429A1 (es)
SG (1) SG172039A1 (es)
TW (1) TW201029662A (es)
UY (1) UY32341A (es)
WO (1) WO2010070094A1 (es)
ZA (1) ZA201104397B (es)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3056568T3 (da) 2006-03-31 2021-11-01 Chugai Pharmaceutical Co Ltd Fremgangsmåder til kontrollering af antistoffers blodfarmakokinetik
CN106519025B (zh) 2007-09-26 2021-04-23 中外制药株式会社 利用cdr的氨基酸取代来改变抗体等电点的方法
KR102469853B1 (ko) 2008-04-11 2022-11-22 추가이 세이야쿠 가부시키가이샤 복수 분자의 항원에 반복 결합하는 항원 결합 분자
JO3340B1 (ar) 2010-05-26 2019-03-13 Regeneron Pharma مضادات حيوية لـعامل تمايز النمو 8 البشري
AU2011337704B2 (en) 2010-11-30 2017-06-15 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule capable of binding to plurality of antigen molecules repeatedly
EP2714084B1 (en) 2011-06-02 2019-05-22 Dyax Corp. Fc RECEPTOR BINDING PROTEINS
ES2663946T3 (es) 2011-11-14 2018-04-17 Regeneron Pharmaceuticals, Inc. Composiciones y métodos para aumentar la masa y la fuerza muscular antagonizando específicamente GDF8 y/o Activina A
SG10201709559PA (en) 2012-08-24 2017-12-28 Chugai Pharmaceutical Co Ltd Fcγriib-specific fc region variant
EP3597747B1 (en) 2012-08-24 2023-03-15 Chugai Seiyaku Kabushiki Kaisha Mouse fcgammarii-specific fc antibody
MY172863A (en) * 2012-09-13 2019-12-13 Bristol Myers Squibb Co Fibronectin based scaffold domain proteins that bind to myostatin
US11267868B2 (en) 2013-04-02 2022-03-08 Chugai Seiyaku Kabushiki Kaisha Fc region variant
SG10201913751RA (en) 2013-05-06 2020-03-30 Scholar Rock Inc Compositions and methods for growth factor modulation
TW201920262A (zh) 2013-07-30 2019-06-01 美商再生元醫藥公司 抗活化素ａ之抗體及其用途
CA3005158A1 (en) 2014-11-06 2016-05-12 Scholar Rock, Inc. Anti-pro/latent-myostatin antibodies and uses thereof
PE20221834A1 (es) 2014-12-19 2022-11-29 Chugai Pharmaceutical Co Ltd Anticuerpos antimiostatina
KR20170110129A (ko) 2015-02-05 2017-10-10 추가이 세이야쿠 가부시키가이샤 이온 농도 의존적 항원 결합 도메인을 포함하는 항체, Fc 영역 개변체, IL-8에 결합하는 항체, 및 그들의 사용
EP3283519A1 (en) 2015-04-15 2018-02-21 Regeneron Pharmaceuticals, Inc. Methods of increasing strength and functionality with gdf8 inhibitors
LT3350220T (lt) 2015-09-15 2021-09-27 Scholar Rock, Inc. Anti pro/latentinio miostatino antikūnai ir jų panaudojimas
AU2016372934B2 (en) * 2015-12-18 2023-10-05 Chugai Seiyaku Kabushiki Kaisha Anti-myostatin antibodies, polypeptides containing variant Fc regions, and methods of use
US11359009B2 (en) 2015-12-25 2022-06-14 Chugai Seiyaku Kabushiki Kaisha Anti-myostatin antibodies and methods of use
CN109071645A (zh) 2016-01-08 2018-12-21 供石公司 抗-原肌生长抑制素/潜伏肌生长抑制素抗体及其使用方法
KR102271635B1 (ko) 2016-06-13 2021-07-06 스칼러 락, 인크. 미오스타틴 억제제의 용도 및 조합 요법
KR102456739B1 (ko) * 2016-06-17 2022-10-19 추가이 세이야쿠 가부시키가이샤 항-마이오스타틴 항체 및 사용 방법
CN116251182A (zh) 2016-08-05 2023-06-13 中外制药株式会社 用于预防或治疗il-8相关疾病的组合物
FR3055548B1 (fr) 2016-09-05 2018-09-28 Metabrain Research Utilisation de metabolites du tryptophane dans le traitement de l'atrophie musculaire
WO2018129395A1 (en) * 2017-01-06 2018-07-12 Scholar Rock, Inc. Methods for treating metabolic diseases by inhibiting myostatin activation
FI3565592T3 (fi) * 2017-01-06 2023-05-10 Scholar Rock Inc Metabolisten tautien hoitaminen estämällä myostatiinin aktivaatio
CN111787981A (zh) 2018-03-01 2020-10-16 瑞泽恩制药公司 改变身体组成的方法
CN113195532A (zh) 2018-12-18 2021-07-30 瑞泽恩制药公司 使用针对瘦素受体、gdf8和活化素a的拮抗剂增加体重和瘦肌肉质量的组合物和方法
WO2023069605A1 (en) * 2021-10-20 2023-04-27 Arizona Board Of Regents On Behalf Of Arizona State University Systems, methods, and apparatuses for implementing a cloud-based health, nutritional, and body composition analysis platform
WO2024064842A1 (en) 2022-09-21 2024-03-28 Regeneron Pharmaceuticals, Inc. Methods of treating obesity, diabetes, and liver dysfunction

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS57106673A (en) 1980-12-24 1982-07-02 Chugai Pharmaceut Co Ltd Dibenzo(b,f)(1,4)oxazepin derivative
DD266710A3 (de) 1983-06-06 1989-04-12 Ve Forschungszentrum Biotechnologie Verfahren zur biotechnischen Herstellung van alkalischer Phosphatase
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US4879231A (en) 1984-10-30 1989-11-07 Phillips Petroleum Company Transformation of yeasts of the genus pichia
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
GB8610600D0 (en) 1986-04-30 1986-06-04 Novo Industri As Transformation of trichoderma
EP0307434B2 (en) * 1987-03-18 1998-07-29 Scotgen Biopharmaceuticals, Inc. Altered antibodies
KR0184860B1 (ko) 1988-11-11 1999-04-01 메디칼 리써어치 카운실 단일영역 리간드와 이를 포함하는 수용체 및 이들의 제조방법과 이용(법)
FR2646437B1 (fr) 1989-04-28 1991-08-30 Transgene Sa Nouvelles sequences d'adn, leur application en tant que sequence codant pour un peptide signal pour la secretion de proteines matures par des levures recombinantes, cassettes d'expression, levures transformees et procede de preparation de proteines correspondant
US6291158B1 (en) 1989-05-16 2001-09-18 Scripps Research Institute Method for tapping the immunological repertoire
EP0402226A1 (en) 1989-06-06 1990-12-12 Institut National De La Recherche Agronomique Transformation vectors for yeast yarrowia
US6172197B1 (en) 1991-07-10 2001-01-09 Medical Research Council Methods for producing members of specific binding pairs
DK0605522T3 (da) 1991-09-23 2000-01-17 Medical Res Council Fremgangsmåde til fremstilling af humaniserede antistoffer
GB9122820D0 (en) 1991-10-28 1991-12-11 Wellcome Found Stabilised antibodies
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
GB9203459D0 (en) 1992-02-19 1992-04-08 Scotgen Ltd Antibodies with germ-line variable regions
ATE149570T1 (de) 1992-08-17 1997-03-15 Genentech Inc Bispezifische immunoadhesine
DE69432815T2 (de) 1993-03-19 2003-12-11 Univ Johns Hopkins Med Wachstumsfaktor-8
GB2294267B (en) 1993-06-03 1996-11-20 Therapeutic Antibodies Inc Anti-TNFalpha Fab fragments derived from polyclonal IgG antibodies
US5429746A (en) 1994-02-22 1995-07-04 Smith Kline Beecham Corporation Antibody purification
US5795737A (en) 1994-09-19 1998-08-18 The General Hospital Corporation High level expression of proteins
US5739277A (en) 1995-04-14 1998-04-14 Genentech Inc. Altered polypeptides with increased half-life
ES2274566T3 (es) 1997-02-07 2007-05-16 MERCK & CO., INC. Genes gag del vih sinteticos.
DE19742706B4 (de) 1997-09-26 2013-07-25 Pieris Proteolab Ag Lipocalinmuteine
GB9806530D0 (en) 1998-03-26 1998-05-27 Glaxo Group Ltd Inflammatory mediator
IL127127A0 (en) 1998-11-18 1999-09-22 Peptor Ltd Small functional units of antibody heavy chain variable regions
US6818418B1 (en) 1998-12-10 2004-11-16 Compound Therapeutics, Inc. Protein scaffolds for antibody mimics and other binding proteins
US7115396B2 (en) 1998-12-10 2006-10-03 Compound Therapeutics, Inc. Protein scaffolds for antibody mimics and other binding proteins
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
EP1229125A4 (en) 1999-10-19 2005-06-01 Kyowa Hakko Kogyo Kk PROCESS FOR PRODUCING A POLYPEPTIDE
EP1332209B1 (en) 2000-09-08 2009-11-11 Universität Zürich Collections of repeat proteins comprising repeat modules
WO2004006955A1 (en) 2001-07-12 2004-01-22 Jefferson Foote Super humanized antibodies
NZ592087A (en) 2001-08-03 2012-11-30 Roche Glycart Ag Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity
US7320789B2 (en) * 2001-09-26 2008-01-22 Wyeth Antibody inhibitors of GDF-8 and uses thereof
GB0216648D0 (en) 2002-07-18 2002-08-28 Lonza Biologics Plc Method of expressing recombinant protein in CHO cells
TWI323265B (en) 2002-08-06 2010-04-11 Glaxo Group Ltd Antibodies
BRPI0314814C1 (pt) 2002-09-27 2021-07-27 Xencor Inc anticorpo compreendendo uma variante de fc
AR047392A1 (es) * 2002-10-22 2006-01-18 Wyeth Corp Neutralizacion de anticuerpos contra gdf 8 y su uso para tales fines
EP2368578A1 (en) 2003-01-09 2011-09-28 Macrogenics, Inc. Identification and engineering of antibodies with variant Fc regions and methods of using same
AU2004253835B2 (en) 2003-07-04 2009-01-29 Affibody Ab Polypeptides having binding affinity for HER2
AU2003275958A1 (en) 2003-08-25 2005-03-10 Pieris Proteolab Ag Muteins of tear lipocalin
KR20060129246A (ko) 2003-12-05 2006-12-15 컴파운드 쎄라퓨틱스, 인크. 타입 2 혈관 내피 성장 인자 수용체의 억제제
ES2384176T3 (es) 2004-03-23 2012-07-02 Eli Lilly & Company Anticuerpos anti-miostatina
AU2005269759A1 (en) 2004-07-21 2006-02-09 Glycofi, Inc. Immunoglobulins comprising predominantly a GlcNAc2Man3GlcNAc2 glycoform
GB0425555D0 (en) 2004-11-19 2004-12-22 Glaxo Group Ltd Novel compounds
EP1877075A4 (en) * 2005-04-25 2008-07-30 Pfizer ANTIBODIES DIRECTED AGAINST MYOSTATIN
US8221998B2 (en) 2005-05-20 2012-07-17 Glaxosmithkline Llc Expression of protein GB1 domain fusion proteins in mammalian cells
ES2534760T3 (es) * 2005-08-19 2015-04-28 Wyeth Llc Anticuerpos antagonistas contra GDF-8 y sus usos en el tratamiento de ELA y otros trastornos asociados con GDF-8
KR101135220B1 (ko) 2005-10-06 2012-04-24 일라이 릴리 앤드 캄파니 항-마이오스타틴 항체
UA92504C2 (en) 2005-10-12 2010-11-10 Эли Лилли Энд Компани Anti-myostatin monoclonal antibody
PL2066695T3 (pl) 2006-09-05 2013-08-30 Lilly Co Eli Przeciwciała przeciwko miostatynie
GB0702888D0 (en) * 2007-02-14 2007-03-28 Glaxo Group Ltd Novel Antibodies
EP1958957A1 (en) 2007-02-16 2008-08-20 NascaCell Technologies AG Polypeptide comprising a knottin protein moiety

Also Published As

Publication number Publication date
WO2010070094A1 (en) 2010-06-24
UY32341A (es) 2010-07-30
CR20110358A (es) 2011-10-04
JP2012512641A (ja) 2012-06-07
SG172039A1 (en) 2011-07-28
CL2011001503A1 (es) 2012-02-03
IL213243A0 (en) 2011-07-31
EA201190018A1 (ru) 2013-02-28
MA32980B1 (fr) 2012-01-02
DOP2011000189A (es) 2011-07-31
CO6400149A2 (es) 2012-03-15
MX2011006611A (es) 2011-06-30
CN102325793A (zh) 2012-01-18
US20110256132A1 (en) 2011-10-20
BRPI0922405A2 (pt) 2018-10-23
TW201029662A (en) 2010-08-16
NZ593297A (en) 2012-10-26
PE20120429A1 (es) 2012-05-08
AU2009329533A1 (en) 2011-06-30
KR20110103431A (ko) 2011-09-20
CA2747062A1 (en) 2010-06-24
ZA201104397B (en) 2012-11-28
EP2358753A1 (en) 2011-08-24

Similar Documents

Publication Publication Date Title
AR074777A1 (es) Proteinas de union a antigeno
UY33421A (es) Proteinas de union al antígeno humanizados
CR20120310A (es) Anticuerpos neutralizadores contra el receptor de prolactina y su uso terapéutico
EP4276114A3 (en) Cd20 binding single domain antibodies
ECSP11011297A (es) Proteinas ligadoras il-17
AR074360A1 (es) Anticuerpo monoclonal o fragmento de union a antigeno del mismo composicion farmaceutica que lo comprende y su uso para preparar dicha composicion
EA201400579A1 (ru) Антитела к il-36r
MX2019006362A (es) Una combinacion de inmunoconjugado y anticuerpo para usarse en el tratamiento de cancer.
CO7250445A2 (es) Proteínas de unión a antígeno st2
CO6290772A2 (es) Anticuerpos dirigidos a angiopoietina 1 y angiopoietina 2 y usos de los mismos
BR112014015851A2 (pt) proteínas de ligação específicas duplas direcionadas contra il-13 e/ou il-17
GT201200313A (es) 5-fluoro-1h-pirazolopiridinas sustituidas y su uso
EA201401077A1 (ru) Биспецифические антитела к человеческому tweak и человеческому il17 и их применения
UA118332C2 (uk) Білок, що зв'язує антиген cd27l
IL221205A (en) Antibody Couplings Binding to B10F2P161 Proteins Containing and Using Them
EA201390993A1 (ru) Антитела к cd38
MX2011011754A (es) Composiciones y metodos para anticuerpos que se dirigen a la proteina de complemento c3b.
WO2014144280A3 (en) Dual specific binding proteins directed against il-1 beta and il-17
UY36561A (es) Nuevas proteínas específicas para pioverdina y pioquelina
IL237345B (en) Antibody and drug conjugates (adc) that bind to 158p1d7 proteins, preparations containing them and their uses
JO2721B1 (en) Derivatives of artemisia plant and its preparations and therapeutic applications
EA201500363A1 (ru) Человеческие анти-vegfr-2/kdr-антитела
CR20120491A (es) Proteinas de unión a antigeno especificas para el componente amiloide serico p
EA201690321A1 (ru) Применение иммуноконъюгата антитела к muc1 и майтанзиноида для лечения солидных опухолей
CO2017007874A2 (es) Composiciones y métodos para metabolismo muscular mejorado

Legal Events

Date Code Title Description
FA Abandonment or withdrawal